Common Nasal Decongestant Doesn ’ t Actually Work, According to FDA Advisors

A panel of US regulatory advisers said phenylephrine, a main component of over-the-counter cold medicines including some versions of Procter & Gamble Co.’s Nyquil, doesn’t actually work. The committee of 16 advisers to the Food and Drug Administration voted unanimously on Tuesday that scientific evidence doesn’t prove that the nasal decongestant is effective when taken orally at recommended doses. The majority of panelists agreed that further studies to test higher doses of the drug would not be worthwhile.  [time-brightcove not-tgx=”true”] The advisory committee’s decision isn’t binding, but the FDA’s own staff have also questioned phenylephrine’s efficacy. If the agency follows the panel’s recommendation, it could next begin a process to remove the drug from the market, forcing manufacturers, including P&G, Kenvue Inc. (Sudafed) and Reckitt Benckiser Group (Mucinex), to reformulate many popular cough and cold products.  The companies didn’t respond to requests for comment. Consumers spent about $1.8 billion on products containing phenylephrine in 2022, according to the FDA, although many cold remedies with the decongestant also contain other active ingredients like antihistamines and cough suppressants.  Phenylephrine has increasingly been used as a substitute for pseudoephedrine in many non-prescription cold remedies. Commonly found in forms of Sudafed, pseudo...
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized wire Source Type: news